Tremelimumab Biosimilar, CTLA-4 Monoclonal Antibody

Additional Information:
| Tremelimumab Biosimilar, CTLA-4 monoclonal antibody Recombinant Chimeric IgG2 Monoclonal Antibody. |Isotype: Human IgG2 kap|The anti-human CTLA-4 monoclonal antibody tremelimumab biosimilar (research grade) was produced in mammal cells. |Specificity/Sensitivity: The in vivo grade tremelimumab biosimilar specifically binds to the human protein receptor CD152 / CTLA4. |Applications: ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological |0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |Endotoxin: |Purity: >95% by SDS-|The research grade tremelimumab biosimilar is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |Background What is Tremelimumab biosimilar research grade? Tremelimumab (formerly ticilimumab) is a fully human monoclonal antibody against CTLA-4 / CD152. It is an immune checkpoint blocker. Unlike Ipilimumab (another fully human anti-CTLA-4 / CD152 monoclonal antibody), which is an IgG1 isotype, tremelimumab is an IgG2 isotype.Tremelimumab Biosimilar uses the same protein sequences as the therapeutic antibody tremelimumab. Tremelimumab aims to stimulate an immune system attack on tumors. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism (immune checkpoint) that interrupts this destruction. Tremelimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy the cancer cells. This is immune checkpoint blockade. Tremelimumab binds to the protein CTLA-4 / CD152, which is expressed on the surface of activated T lymphocytes and inhibits the killing of cancer cells. Tremelimumab blocks the binding of the antigen-presenting cell ligands B7.1 and B7.2 to CTLA-4 / CD152, resulting in inhibition of B7-CTLA-4-med downregulation of T-cell activation; subsequently, B7.1 or B7.2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-med T-cell activation unopposed by B7-CTLA-4-med inhibition. Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars: Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody PD-1 is a member of the extended CD28/CTLA-4 family of T cell regulators. Syd Labs provides the following research grade anti-PD-L1 / PD-1 antibody biosimilar proteins: Atezolizumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Avelumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Camrelizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody Cemiplimab biosimilar, research grade, anti-human PD-1 monoclonal antibody Durvalumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody Spartalizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody